Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Inc. Matt Biegler; Analyst; Oppenheimer and Co. Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost ...

Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...

Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

FDA grants accelerated approval to Gilead's Livdelzi for PBC FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) has received accelerated approval from the U.S. Food and Drug Administration ...

(RTTNews) - Gilead Sciences Inc. (GILD) released earnings for third quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.253 billion ...

MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada) announced that Paul Petrelli joined the organization as Vice ...

Shares of Gilead Sciences Inc. GILD rallied 1.63% to $91.69 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 2.53% to ...